EPHA1 and acute lymphoblastic leukemia: In this section, we will outline the reported role of EPH/ephrins in pediatric hematologic malignancies, primarily focusing on T-cell ALL (T-ALL), which presents relapse in most pediatric patients, despite the use of chemotherapeutic agents, novel agents targeting lymphocyte signaling pathways (i.e., Notch1, JAK, and BCL2 inhibitors), steroids, and allogeneic stem cell transplantation [130].